dacarbazine has been researched along with alpha-asarone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q | 2 |
2 other study(ies) available for dacarbazine and alpha-asarone
| Article | Year |
|---|---|
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Rats; RNA, Messenger; Temozolomide | 2017 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Autophagy; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Shape; Dacarbazine; Glioma; Humans; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2018 |